Dear Sir, The intraperitoneal heparin concentration in CAPD is based on clinical observations [1, 2] and differs from center to center [3] . The aim of an intraperitoneal hepar-inization should be a sufficient inhibition of intraperitoneal fibrin formation without a systemic anticoagulatory effect. The determination of fibrinopeptide A (FPA), a specific marker for thrombin action on fibrinogen, enables the control of fibrin monomer production by thrombin [4, 5] . In 6 patients with diabetic end-stage renal failure we investigated the FPA concentration in dialysate after 500 and 7,500 U heparin/1 dialysate for a dwell time of 4h (table I) . Intraperitoneal heparin reduces the fibrin production measurable as FPA concentration. There was no difference between 7,500 and 500 U/l heparin intraperitoneally. During the experiments with 500 U/l heparin one additional patient got peritonitis (by Achromobacter xylo-soxidans) with an increase of total protein from 58.9 to 209.8 mg/dl and of antithrombin III (AT III) from 0.32 to 1.04 mg/dl in 4-hour dialysate. The FPA concentration remained at 6.3 ng/ml as in his heparinized dialysate without peritonitis. There was no increased fibrinogen cleavage. A second patient with end-stage renal failure, CAPD treatment and an extended myocardial infarction in the past got peritonitis by Pseudomonas aeruginosa. The initial leukocytosis in dialysate was 23,000/µl. The peritonitis was treated successfully with intraperitoneal ticar-cillin and with 500 U heparin per liter dialysate for some weeks. Ten weeks after the peritonitis the patient died of sudden ventricular fibrillation. At autopsy the peritoneum had a glossy surface without any fibrin deposits or visible alterations. Table I . Concentrations in dialysate after a 4-hour dwell time (x ± SEM) Heparin, U/l 7,500 500 0 ATIII‚mg/dl 0.33 ± 0.06 0.44 ± 0.13 0.45 ± 0.07 FPA, ng/ml 20.6 ± 5.6* 22.8 ± 6.0* 152.2 ± 11.8 * Significant versus dialysate without heparin (p < 0.05).
